Эффективность и безопасность пантопразола в лечении пациентов с кислотозависимыми заболеваниями в России: многоцентровое наблюдательное исследование

Abstract

The aim – evaluate the clinical effect and adherence to pantoprazole (Nolpaza®) therapy in patients with acid-dependent diseases in real clinical practice. Pantoprazole occupies a special place among various representatives of proton pump inhibitors (PPI) due to the peculiarities of its pharmacokinetics and pharmacodynamics. Thus, the area under the curve (AUC), correlating with the severity of acid-suppressive effect, is significantly higher for pantoprazole than for other PPIs. In addition, pantoprazole has a longer-lasting antisecretory effect because it is the only PPI that binds to both cysteine 813 and deep-lying cysteine 822. Of all PPIs, pantoprazole least blocks the CYP2C19 isoenzyme involved in multidrug metabolism, ensuring minimal drug interactions. Material and methods. Data collection for further analysis was performed using specially designed electronic individual registration cards of two groups of patients: the first – patients with gastroesophageal reflux disease (GERD), receiving therapy with Nolpaza®; the second – patients with peptic ulcer disease (PU) / erosive gastritis and patients with an indication for Helicobacter pylori eradication, receiving therapy with Nolpaza® as part of the eradication therapy regimen. Conclusion. According to the results of the conducted study it was possible to evaluate the clinical effect and tolerability of Nolpaza® therapy using the data of more than 14 thousand patients with GERD, gastritis, duodenitis, gastric and duodenal ulcer, drug-induced gastropathy, 98% of whom had gastrointestinal complaints before the beginning of treatment, while by the end of therapy the complaints remained in full in less than 1% of patients. The results of esophagogastroduodenoscopy at the end of therapy with Nolpaza® confirmed positive dynamics in 99.8% of cases, and the vast majority of patients achieved complete endoscopic remission. Positive dynamics was also observed in the majority of patients who were tested for H. pylori infection. The efficacy of eradication therapy with Nolpaza® amounted to 88.2%. The study provided a high assessment of patient adherence throughout the follow-up period.